Aurora Cannabis Announces Fiscal 2027 First Quarter Results
Aurora Cannabis (NASDAQ: ACB, TSX: ACB) reported fiscal 2027 Q1 results for the quarter ended June 30, 2026. Net revenue was $67.6 million, down from $74.1 million. International medical cannabis net revenue rose 17% to $43.3 million, while Canadian medical cannabis fell 25% to $20.7 million. The company had $149.1 million cash and no debt, and posted a $4.0 million net loss from continuing operations.
How this was made
The 30-second read
Why it matters
Key drivers were a Canadian federal reimbursement program change effective April 1, 2026 that lowered reimbursement rates by about 30%, partially offset by higher international medical cannabis sales (notably Germany). The company also emphasized Safari’s EU-GMP certification and planned growth capital to reduce reliance on third-party suppliers.
Market read
Traders get a fresh earnings-and-segment read: international growth and EU-GMP capacity progress versus Canadian reimbursement-driven margin and EBITDA deterioration, plus a stated expectation for sequential Q2 improvement.
What to watch
The article notes sequential Q2 improvement but does not quantify it; traders may need to watch whether EU-GMP capacity investment ($3.5M over three years) meaningfully improves margins versus only improving availability.
Background
Aurora Cannabis (ACB) reported fiscal Q1 2027 results for the quarter ended June 30, 2026, after exiting low-margin Canadian consumer and plant propagation businesses and acquiring Safari Flower Company for EU-GMP capacity.
Ticker impact
Aurora Cannabis reported fiscal Q1 2027 results, including $67.6M net revenue, international growth, and a lower Canadian reimbursement-driven margin.
Near-term volatility likely tied to margin/EBITDA weakness versus the forward sequential improvement expectation and EU-GMP capacity narrative.
The article provides detailed segment drivers (Canada reimbursement rate change, Germany demand) plus a specific operational catalyst (Safari EU-GMP certification and planned $3.5M investment) and reiterates an unchanged full-year outlook with sequential Q2 improvement.
Market effects
Highlights ongoing EU-GMP manufacturing buildout as a competitive differentiator in international medical cannabis, while Canadian reimbursement policy remains a key margin swing factor.
Canada-focused medical cannabis names may face sentiment pressure from reimbursement-rate changes; Germany demand appears supportive for international peers.
Reinforces that EU-GMP capacity and regulatory compliance are central to scaling medical cannabis exports into higher-margin markets.
Counterpoint
International revenue growth may not translate into earnings power if adjusted gross margin continues to compress due to reimbursement and cost structure changes.
Key entities
- companyAurora Cannabis Inc.
Canada-based global medical cannabis company reporting fiscal Q1 2027 results and reiterating full-year outlook.
- companySafari Flower Company
EU-GMP certified indoor cultivation and manufacturing facility acquired by Aurora, with a three-year EU-GMP certification for its Ontario facility.
- companyBevo Agtech Inc.
Aurora divested its 50.1% ownership interest; Bevo is excluded from comparative figures as a discontinued operation.
